Supply and procurement

Meningococcal Outbreak Response Supply and Procurement Roadmap UPDATE 1ST October 2019 Page 1 The Market Shaping Goal Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries. Supply and Procurement Roadmap Meningococcal Vaccines for Outbrea

Gavi, the Vaccine Alliance is supporting countries to improve vaccine visibility and traceability from manufacturer to beneficiary, contributing to our efforts to secure quality assured vaccines delivered to the right place, in the right quantities, at the right time to all children and adolescents.

GaviGaviGaviGavi-supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supported pneumococcal supp

Gavi established the Cold Chain Equipment Optimisation Platform (CCEOP) in June 2015 as a strategic and targeted approach to address the challenges of improving the vaccine cold chain with higher-performing equipment. This document provides a summary of the supply and procurement roadmap for two CCE product categories : Ice-lined (ILR) & Solar Direct Drive (SDD) refrigerators/ freezers.

In 2017, a framework by which to assess whether Gavi’s market shaping activities caused unintended consequences in vaccine markets was developed. In accordance with the externalities framework, an external party conducted the first monitoring phase, driven by quantitative data and qualitative consultations with a wide variety of stakeholders. This public summary outlines the findings of this phase of monitoring.

Rotavirus Vaccine Profiles support countries in their decision making process by providing up-to-date and comprehensive information about the Rotavirus vaccines supported by Gavi. The slides include information about availability of prequalified vaccines, efficacy, effectiveness and safety data, estimation of direct cost, storage, transportation and programmatic administration considerations.

Gavi opened a funding window for typhoid conjugate vaccine in November 2017, supporting catch-up campaigns and co-financing of the vaccine use in routine immunisation programmes. This document is the public summary of the supply and procurement roadmap for TCV.

Gavi, the Vaccine Alliance opened a funding window for Japanese encephalitis (JE) vaccination catch-up campaigns in endemic countries at its November 2013 Board meeting. This document is the public summary of the supply and procurement roadmap for JE, which supports the Alliance’s efforts to achieve our market shaping goal – to shape vaccine markets to ensure sufficient, secure supply of suitable, quality vaccines at appropriate and sustainable prices for developing countries.

In its 2016-2020 Supply and Procurement Strategy, the Alliance has committed to monitor the unintended consequences of Gavi market shaping activities in Gavi and non-Gavi supported countries. This document is the public summary of the framework of key potential Gavi market shaping externalities, including indicators to monitor those.

In 2014, Gavi has committed to purchase Ebola vaccine for a global stockpile as soon as a safe, effective vaccine is recommended for use by the World Health Organization. This document is the public summary of the supply and procurement roadmap for Ebola vaccine.

Complementing activities under its third strategic goal (SG3: ‘improve sustainability of national immunisation programmes’), the Alliance has committed to support transitioning countries to make well-informed, country-owned procurement decisions. This document is the public summary of the supply and procurement roadmap for country-owned decisions.

HPV Supply and Procurement Roadmap 2017.

The Base Demand Forecast summarises actual and forecasted volumes for eleven vaccines that Gavi supports. The volumes presented are from the demand forecast used to inform the Gavi Financial forecast.

In June 2017, Gavi, the Vaccine Alliance launched a public consultation process on externalities of market shaping. The consultation was open from 26 June 2017 to 02 August 2017. This document provides an overview of the process, as well as a summary of the main themes that emerged from the comments received. It does not necessarily reflect the views of Gavi, the Vaccine Alliance.

In 2013, the GAVI Board decided to begin supporting the introduction of inactivated polio vaccine (IPV) as part of routine immunisation programmes in the world’s 73 poorest countries. This document is the public summary of the supply and procurement roadmap for IPV, which supports the Alliance’s efforts to achieve our market shaping goal – to shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries.

Gavi, the Vaccine Alliance, developed the Healthy Markets Framework (HMF) as a tool to support market shaping.

Rotavirus is the leading cause of severe diarrhoea in children under five years of age worldwide. This document is the public summary of the supply and procurement roadmap for rotavirus vaccine.

Gavi has supported routine introductions with pneumococcal vaccine since 2009. Find out more about the pneumococcal vaccine market, and Gavi’s approach to shaping it, in the public summary of the vaccine supply and procurement roadmap.

The development of hepatitis B (hepB) and Haemophilus influenzae type b (Hib) vaccination through the uptake of pentavalent routine immunization represents the most significant Gavi achievement to date.

Gavi has been engaged in Yellow Fever (YF) vaccination since 2001 in support of WHO efforts to control the disease. This document is the public summary of the supply and procurement roadmap for Yellow Fever vaccine.

Gavi’s Supply and Procurement Strategy describes the Alliance’s activities towards strategic goal 4 (SG4), to shape markets for vaccines and other immunisation products, to the benefit of the countries that Gavi supports. This document provides a short overview of the strategy.

As part of the Supply and Procurement Strategy 2016-20, the Gavi Board approved a set of principles which guides decisions on when to offer support for a specific vaccine or other immunisation product through an open funding window.

Vaccine price commitments from Merck – October 2015.

Vaccine price commitments from manufacturers.

Vaccine price commitments from GlaxoSmithKline.

Gavi’s Supply and Procurement Strategy describes the Alliance’s activities towards strategic goal 4 (SG4), to shape markets for vaccines and other immunisation products, to the benefit of the countries that Gavi supports.

Vaccine price commitments from Pfizer – June 2015.

Gavi is engaged in meningococcal vaccine to eliminate serogroup A meningococcal meningitis (MenA) epidemics as a public health problem in Africa. This document is the public summary of the supply and procurement roadmap for menigococcal vaccine, which supports the Alliance’s efforts to achieve our market shaping goal – to shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries.

Vaccine price commitments from Biological E – January 2015.

Vaccine price commitments from Janssen Pharmaceuticals – January 2015.

Vaccine price commitments from Panacea Biotec – January 2015.

Gavi is funding the procurement of oral cholera vaccine from 2014-2018 via the existing cholera vaccine stockpile, managed by the International Coordination Group (ICG). This document is the public summary of the supply and procurement roadmap for cholera vaccine, which supports the Alliance’s efforts to achieve our market shaping goal – to shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries.

Gavi’s engagement on measles dates to 2004 and rubella support began in 2011 through the measles-rubella (MR) vaccine. By the end of 2016, Gavi had supported 50 countries with MR programmes. This public summary of the supply and procurement roadmap describes the market, and outlines Gavi’s market shaping ambitions for MR vaccines.

1 The GAVI Alliance Vaccine Supply and Procurement Strategy for the period 2011-2015 VERSION NUMBER APPROVAL PROCESS DATE 1.0 Reviewed by: GAVI Programme and Policy Committee 28 September 2011 Approved by: GAVI Alliance Board 17 November 2011 Effective from: approval date Review: in 2014, in preparation for the develop

In July 2011 the GAVI Secretariat launched a public consultation process on the draft Vaccine Supply and Procurement Strategy for 2011-2015. The consultation was open from 4 to 29 July 2011. This document provides an overview of the process, as well as a summary of the main themes that emerged from the comments received.

In order to achieve its market shaping objectives, GAVI is redesigning its vaccine supply and procurement strategy. This document outlines the objectives and strategies, and describes the supply and procurement mechanisms by which the new strategy will be effected.

This document provides background information to GAVI's Draft Vaccine Supply and Procurement Strategy for the period 2011-2015, made available for public consultation.

GAVI recognizes immunisation as an important and potentially cost-effective intervention that can enhance the right of all children to a healthy life, that has positive effects in combating poverty and that is a critical contribution to the achievement of public health gains.

Recommendations and analysis of the GAVI supply strategy task team for a supply and procurement stragety for Hib and HebB containing vaccines during the GAVI Board meeting, 6-7 December 2005, in Delhi, India.

Summary of the findings of a study commissioned by the Vaccine Fund and the GAVI FInancing Task Force Procurement Sub-group to examine the first procurement of vaccines by GAVI and the Vaccine Fund.